Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AX Other antipsychotics
N05AX08 Risperidone
D00426 Risperidone (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antipsychotics
2nd Generation/Atypical
Risperidone
D00426 Risperidone (JP18/USP/INN)
Bipolar Agents
Bipolar Agents, Other
Risperidone
D00426 Risperidone (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
117 Psychotropics
1179 Others
D00426 Risperidone (JP18/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
D00426 Risperidone
DG03005 Serotonin-dopamine antagonist (SDA)
D00426 Risperidone
DG03200 Antipsychotic agent
DG03064 Atypical antipsychotic
D00426 Risperidone
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
D00426 Risperidone
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D00426 Risperidone
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D00426 Risperidone (JP18/USP/INN) <JP/US>
Serotonin
HTR2A
D00426 Risperidone (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00426 Risperidone
D00426 Risperidone tablets
D00426 Risperidone fine granules
D00426 Risperidone solution
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00426
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00426
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00426
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00426
Prodrugs [br08324.html]
D00426